2268.HK
2268.HK
KYG9808A1058
WUXI XDC
Loading chart...

Company Profile

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

Related stocks

SAILIFE.NS
SAILIFE.NS • India
SAI LIFE SCIENCES LIMITED
1,487.9 INR
3.27B USD 1Y +74.7%
300347.SZ
300347.SZ • China
TIGERMED
55.18 CNY
7.11B USD 1Y -3%
3347.HK
3347.HK • China
TIGERMED
44.56 HKD
4.89B USD 1Y +3.2%
603127.SS
603127.SS • China
JOINN LABORATORIES (CHINA) CO L
52.6 CNY
5.9B USD 1Y +47.6%
603882.SS
603882.SS • China
GUANGZHOU KINGMED DIAGNOSTICS G
28.82 CNY
2B USD 1Y -3.4%
603259.SS
603259.SS • China
WUXI APPTEC CO LTD
157.8 CNY
71.66B USD 1Y +39.8%
300676.SZ
300676.SZ • China
BGI GENOMICS
45.47 CNY
2.85B USD 1Y -9.3%
SHL.AX
SHL.AX • Australia
SONIC HLTH FPO [SHL]
18.65 AUD
6.44B USD 1Y -13%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
71.5% p.a.
Max Drawdown (3Y)
-61.1%
Sharpe Ratio (3Y)
0.59
Beta Factor
-0.87
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 64.1 (Elevated multiple compression risk)
ende